Table 1 Clinicopathological baseline characteristics of the 58 evaluable patients
| Â | Experimental | Control | p value |
|---|---|---|---|
Patients (n = 58) | 37 | 21 |  |
Mean age (range) 56.4 (37–80) | 57.0 (37–88) | 55.4 (40–80) | 0.14 |
Menopausal status | Â | Â | Â |
Pre-menopausal | 17 (45.9%) | 10 (47.6%) | 1.0 |
Post-menopausal | 20 (54.1%) | 11 (52.4%) | |
Clinical stage | Â | Â | Â |
 IA | 26 (70.3%) | 17 (81.0%) | 0.74 |
 IB | 0 (0%) | 0 (0%) | |
 IIA | 8 (21.6%) | 4 (19.0%) | |
 IIB | 2 (5.4%) | 0 (0%) | |
 IIIA | 1 (2.70%) | 0 (0%) | |
Histological subtype | Â | Â | Â |
 Carcinoma NOS (ductal) | 21 (56.8%) | 15 (71.4%) | 0.31 |
 Invasive lobular carcinoma | 12 (32.4%) | 3 (14.3%) | |
 Others | 4 (10.8%) | 3 (14.3%) | |
Histological grade | Â | Â | Â |
 G1 | 13 (35.1%) | 4 (19.0%) | 0.43 |
 G2 | 20 (54.1%) | 14 (66.7%) | |
 G3 | 4 (10.8%) | 3 (14.3%) | |
Ki67 | Â | Â | Â |
 < 15 | 16 (43.2%) | 2 (9.5%) | 0.01 |
 15–30 | 12 (32.5%) | 14 (66.7%) | |
 > 30 | 9 (24.3%) | 5 (23.8%) | |
Surrogate molecular subtype | Â | Â | Â |
 Luminal A-like | 19 (51.4%) | 8 (38.1%) | 0.71 |
 Luminal B-like | 12 (32.4%) | 9 (42.9%) | |
 TNBC | 6 (16.22%) | 4 (19.05%) |